Mrs. Carole Monterrat
Carole Monterrat was involved, for the last 10 years in « bench to bedside » clinical product development, primarily at Promethera Biosciences, a Belgian innovative company active in regenerative medicine, then at Sopartec, the Universitécatholique de Louvain (UCL) tech transfer office. She started her career in the pharmaceutical industry as a scientist (Rhône-Poulenc Rorer, UK) then moved to academic research in Bordeaux (France) keeping a strong focus in cell biology. In 2006, she joined the Cell Therapy lab at UCL (Belgium) were she led a spin-off project with Pr Etienne Sokal. At inception of Promethera Biosciences in 2009, Carole joined the spin-off company were she managed administrative and financial issues. Between 2009 and 2014, Promethera successfully raised more than 44 million euros in equity, complemented by more than 10 million euros in grants. In 2014, Carole joined Sopartec as CFO and investment manager of VIVES fund, the UCL fund managed by Sopartec.Sectors of Personal Expertise: Life Sciences
Sopartec is the Technology Transfer and investment company of the Université catholique de Louvain.
Sopartec is the Technology Transfer and investment company of the Université catholique de Louvain. Sopartec's mission, within the Louvain Technology Transfer Office, is to bring the results of research carried out by UCL, the Cliniques universitaires St-Luc and the Institute de Duve(ICP) by creating spin-offs and negotiating licence agreements. Sopartec is also the management company of the Vives Louvain Technology Fund. Vives is a 43 million private seed capital fund that invests in high-technology companies. This multi-sectoral fund supports young companies in all technological sectors, with particular emphasis on eco-innovation projects in both Belgium and neighbouring countries.Tags: